Table 2.
5-AC-treated patients with multiple BM aspirations | |
---|---|
number of patients | 38 |
age, median (range) | 70 (45-85) |
male/female | 19/19 |
WHO 2008 | |
AML/MDS < 30% MB* | 5 |
RAEB I | 9 |
RAEB II | 18 |
RCMD | 2 |
CMML I | 1 |
CMML II | 2 |
MDS/MPN-u | 1 |
IPSS risk group | |
low | 0 |
intermediate I | 9 |
intermediate II | 20 |
high | 4 |
response to 5-AC therapy | |
number of samples at each time point | |
before therapy | 35 |
After 4 cycles | 36 |
After 8 cycles | 18 |
Response as evaluated after 4thcycle | |
number of responders | 20 |
SD with HI | 2 |
PR | 9 |
CR | 2 |
Cri | 7 |
number of non-responders | 16 |
SD without HI | 12 |
PD |
4 |
MDS low risk group |
|
number of patients | 35 |
age at diagnosis, median (range) | 68 (46-83) |
male/female | 9 / 26 |
WHO 2008 | |
MDS 5q | 10 |
RCMD | 21 |
MDS RN | 3 |
MDS/MPN-u | 1 |
IPSS risk group | |
low | 35 |
intermediate I | 0 |
intemediate II | 0 |
high |
0 |
AML sub-group |
|
number of patients | 24 |
age at diagnosis, median (range) | 73.5 (57-86) |
male/female | 16/8 |
WHO 2008 | |
AML/MDS < 30% MB* | 12 |
AML > 30% MB | 12 |
IPSS risk group | |
high | 12 |
not applicable | 12 |
Healthy donors | |
number of donors | 8 |
age at BM aspiration, median (range) | 39 (29-54) |
male/female | 5 / 3 |